This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechnology: Archive
Cytokinetics Gains 20.5% YTD: Buy, Sell or Hold the Stock?
by Zacks Equity Research
Myqorzo's early launch momentum and global expansion could boost Cytokinetics, while pipeline progress may widen its growth opportunity.
CYTKNegative Net Change BMYNegative Net Change BAYRYNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can Yutrepia's Strong Growth Drive Liquidia's PAH Expansion?
by Ekta Bagri
Liquidia's Yutrepia is gaining traction, with $300.3M in first-half sales and nearly 30% of inhaled-market revenues in Q2.
LQDANegative Net Change JNJPositive Net Change UTHRNegative Net Change
biotechnology biotechs medical pharmaceuticals
From COVID to Cancer: Moderna Scores Melanoma Breakthrough
by Andrew Rocco
By successfully applying individualized mRNA technology to train the immune system against recurring tumor cells, Moderna and Merck have opened an extraordinary new frontier in targeted cancer treatment.
MRKNegative Net Change MRNANegative Net Change
biotechnology biotechs
Is Altimmune Worth Buying as Cash Rises but Execution Risks Linger?
by Zacks Equity Research
ALT's stronger cash position supports pemvidutide's MASH, AUD and ALD programs, but long timelines, funding needs and competition remain risks.
ALTNegative Net Change NVONegative Net Change MDGLNegative Net Change
biotechnology
Altimmune's Phase III MASH Study Puts 2029 Data in Investor Focus
by Zacks Equity Research
ALT has moved pemvidutide into Phase III MASH testing, with supportive mid-stage data, regulatory backing and a 2029 readout ahead.
ALTNegative Net Change NVONegative Net Change LLYNegative Net Change
biotechnology
How Does LLY's Q2 GLP-1 Portfolio Performance Stack Up Against NVO's?
by Ahan Chakraborty
Eli Lilly's GLP-1 portfolio outpaces its rival in Q2, while Foundayo gains momentum and can challenge Wegovy's early oral obesity lead.
LLYNegative Net Change NVONegative Net Change VKTXNegative Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
Nuvectis Stock Surges Around 97% in 3 Months: Here's Why
by Zacks Equity Research
NVCT's 97% three-month gain reflects optimism around its expanding pipeline, with NXP100 and NXP200 offering new value drivers.
NVCTNegative Net Change ACIUNegative Net Change AMRXNegative Net Change PGENNegative Net Change
biotechnology
Earnings, Cancer Vaccine, Long-Term Liquidity: A Busy Pre-Market
by Mark Vickery
Q2 retail earnings continue, Moderna sees positive Phase 3 results, and the Treasury lowers the longer-term bond rate.
MRKNegative Net Change TGTNegative Net Change TJXPositive Net Change LOWPositive Net Change ELNegative Net Change MRNANegative Net Change
biotechnology biotechs cancer earnings finance
Latham Group (SWIM)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
SWIMPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy Docebo Inc. (DCBO) After Golden Cross?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
DCBOPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines